IL6 and rheumatoid arthritis: We selected IL6, as it is one of the targets of the biologic treatment in RA [36,41,42,43] and TGF-beta because it is an immunomodulatory cytokine highly expressed in RA patients, with a role that is yet to be determined [44,45,46].